Update Mammakarzinom 2024 Teil 2 – Patientinnen mit Frühstadien des Mammakarzinoms

Zusammenfassung

Diese Übersichtsarbeit fasst die aktuellen Entwicklungen zur Behandlung von Patientinnen mit Frühstadien des Mammakarzinoms zusammen. Die meisten klinisch relevanten Veränderungen sind durch die Einführung der Immuncheckpoint-Inhibitoren bei Patientinnen mit triple-negativem Brusktrebs (TNBC) und der CDK4/6-Inhibitoren bei Patientinnen mit Hormonrezeptor-positiven, HER2-negativen (HRpos/HER2neg) Tumoren und hohem Rückfallrisiko vollzogen worden. Hier entstehen zunehmend Daten mit einer längeren Nachbeobachtungszeit und Integration von translationalen Analysen, die neue Biomarker wie zirkulierende Tumor-DNA (ctDNA) bewerten. In dieser Übersichtsarbeit werden die neuesten Entwicklungen der letzten Monate zusammengefasst und in den jeweiligen Kontext eingeordnet.

Schlüsselwörter

Mammakarzinom - Biomarker - klinische Studien - frühes Mammakarzinom

Publication History

Received: 20 November 2024

Accepted after revision: 07 December 2024

Article published online:
15 May 2025

• References/Literatur

• 1 Stoppa-Lyonnet D, Ansquer Y, Dreyfus H. et al. Familial invasive breast cancers: worse outcome related to BRCA1 mutations. J Clin Oncol 2000; 18: 4053-4059
• 2 Robson ME, Chappuis PO, Satagopan J. et al. A combined analysis of outcome following breast cancer: differences in survival based on BRCA1/BRCA2 mutation status and administration of adjuvant treatment. Breast Cancer Res 2004; 6: R8-R17
• 3 Copson ER, Maishman TC, Tapper WJ. et al. Germline BRCA mutation and outcome in young-onset breast cancer (POSH): a prospective cohort study. Lancet Oncol 2018; 19: 169-180
• 4 Fasching PA, Loibl S, Hu C. et al. BRCA1/2 Mutations and Bevacizumab in the Neoadjuvant Treatment of Breast Cancer: Response and Prognosis Results in Patients With Triple-Negative Breast Cancer From the GeparQuinto Study. J Clin Oncol 2018; 36: 2281-2287
• 5 Fasching PA, Hu C, Hart SN. et al. Susceptibility gene mutations in germline and tumors of patients with HER2-negative advanced breast cancer. NPJ Breast Cancer 2024; 10: 57
• 6 Goodwin PJ, Phillips KA, West DW. et al. Breast cancer prognosis in BRCA1 and BRCA2 mutation carriers: an International Prospective Breast Cancer Family Registry population-based cohort study. J Clin Oncol 2012; 30: 19-26
• 7 Huzarski T, Byrski T, Gronwald J. et al. Ten-year survival in patients with BRCA1-negative and BRCA1-positive breast cancer. J Clin Oncol 2013; 31: 3191-3196
• 8 Verhoog LC, Brekelmans CT, Seynaeve C. et al. Survival and tumour characteristics of breast-cancer patients with germline mutations of BRCA1. Lancet 1998; 351: 316-321
• 9 Rennert G, Bisland-Naggan S, Barnett-Griness O. et al. Clinical outcomes of breast cancer in carriers of BRCA1 and BRCA2 mutations. N Engl J Med 2007; 357: 115-123
• 10 Hahnen E, Lederer B, Hauke J. et al. Germline Mutation Status, Pathological Complete Response, and Disease-Free Survival in Triple-Negative Breast Cancer: Secondary Analysis of the GeparSixto Randomized Clinical Trial. JAMA Oncol 2017; 3: 1378-1385
• 11 Fasching PA, Yadav S, Hu C. et al. Mutations in BRCA1/2 and Other Panel Genes in Patients With Metastatic Breast Cancer-Association With Patient and Disease Characteristics and Effect on Prognosis. J Clin Oncol 2021; 39: 1619-1630
• 12 Cybulski C, Kluzniak W, Huzarski T. et al. Clinical outcomes in women with breast cancer and a PALB2 mutation: a prospective cohort analysis. Lancet Oncol 2015; 16: 638-644
• 13 Schroth W, Goetz MP, Hamann U. et al. Association between CYP2D6 polymorphisms and outcomes among women with early stage breast cancer treated with tamoxifen. JAMA 2009; 302: 1429-1436
• 14 Fasching PA, Loehberg CR, Strissel PL. et al. Single nucleotide polymorphisms of the aromatase gene (CYP19A1), HER2/neu status, and prognosis in breast cancer patients. Breast Cancer Res Treat 2008; 112: 89-98
• 15 Hein A, Lambrechts D, von Minckwitz G. et al. Genetic variants in VEGF pathway genes in neoadjuvant breast cancer patients receiving bevacizumab: Results from the randomized phase III GeparQuinto study. Int J Cancer 2015; 137: 2981-2988
• 16 Hein A, Rack B, Li L. et al. Genetic Breast Cancer Susceptibility Variants and Prognosis in the Prospectively Randomized SUCCESS A Study. Geburtshilfe Frauenheilkd 2017; 77: 651-659
• 17 Pirie A, Guo Q, Kraft P. et al. Common germline polymorphisms associated with breast cancer-specific survival. Breast Cancer Res 2015; 17: 58
• 18 Weischer M, Nordestgaard BG, Pharoah P. et al. CHEK2*1100delC heterozygosity in women with breast cancer associated with early death, breast cancer-specific death, and increased risk of a second breast cancer. J Clin Oncol 2012; 30: 4308-4316
• 19 Muranen TA, Blomqvist C, Dork T. et al. Patient survival and tumor characteristics associated with CHEK2:p. I157 T – findings from the Breast Cancer Association Consortium. Breast Cancer Res 2016; 18: 98
• 20 Guo Q, Schmidt MK, Kraft P. et al. Identification of novel genetic markers of breast cancer survival. J Natl Cancer Inst 2015; 107: djv081
• 21 Stevens KN, Fredericksen Z, Vachon CM. et al. 19p13.1 is a triple-negative-specific breast cancer susceptibility locus. Cancer Res 2012; 72: 1795-1803
• 22 Stevens KN, Vachon CM, Lee AM. et al. Common breast cancer susceptibility loci are associated with triple-negative breast cancer. Cancer Res 2011; 71: 6240-6249
• 23 Breast Cancer Association Consortium. Mavaddat N, Dorling L, Carvalho S. et al. Pathology of Tumors Associated With Pathogenic Germline Variants in 9 Breast Cancer Susceptibility Genes. JAMA Oncol 2022; 8: e216744
• 24 Ghoussaini M, Fletcher O, Michailidou K. et al. Genome-wide association analysis identifies three new breast cancer susceptibility loci. Nat Genet 2012; 44: 312-318
• 25 Kuchenbaecker KB, Ramus SJ, Tyrer J. et al. Identification of six new susceptibility loci for invasive epithelial ovarian cancer. Nat Genet 2015; 47: 164-171
• 26 Michailidou K, Beesley J, Lindstrom S. et al. Genome-wide association analysis of more than 120,000 individuals identifies 15 new susceptibility loci for breast cancer. Nat Genet 2015; 47: 373-380
• 27 Michailidou K, Hall P, Gonzalez-Neira A. et al. Large-scale genotyping identifies 41 new loci associated with breast cancer risk. Nat Genet 2013; 45: 353-361 361e1–361e2
• 28 Milne RL, Kuchenbaecker KB, Michailidou K. et al. Identification of ten variants associated with risk of estrogen-receptor-negative breast cancer. Nat Genet 2017; 49: 1767-1778
• 29 Michailidou K, Lindstrom S, Dennis J. et al. Association analysis identifies 65 new breast cancer risk loci. Nature 2017; 551: 92-94
• 30 Mavaddat N, Michailidou K, Dennis J. et al. Polygenic Risk Scores for Prediction of Breast Cancer and Breast Cancer Subtypes. Am J Hum Genet 2019; 104: 21-34
• 31 Mavaddat N, Michailidou K, Dennis J. et al. Polygenic Risk Scores for Prediction of Breast Cancer and Breast Cancer Subtypes. Am J Hum Genet 2019; 104: 21-34
• 32 Yiangou K, Mavaddat N, Dennis J. et al. Differences in polygenic score distributions in European ancestry populations: implications for breast cancer risk prediction. medRxiv 2024;
• 33 Lopes Cardozo JMN, Andrulis IL, Bojesen SE. et al. Associations of a Breast Cancer Polygenic Risk Score With Tumor Characteristics and Survival. J Clin Oncol 2023; 41: 1849-1863
• 34 Nelson HD, Fu R, Zakher B. et al. Medication Use for the Risk Reduction of Primary Breast Cancer in Women: A Systematic Review for the U.S. Preventive Services Task Force. Rockville, MD: Agency for Healthcare Research and Quality; 2019. Evidence Synthesis No. 180. AHRQ Publication No. 19-05249-EF‑1
• 35 Buijs SM, Koolen SLW, Mathijssen RHJ. et al. Tamoxifen Dose De-Escalation: An Effective Strategy for Reducing Adverse Effects?. Drugs 2024; 84: 385-401
• 36 Lazzeroni M, Puntoni M, Guerrieri-Gonzaga A. et al. Randomized Placebo Controlled Trial of Low-Dose Tamoxifen to Prevent Recurrence in Breast Noninvasive Neoplasia: A 10-Year Follow-Up of TAM-01 Study. J Clin Oncol 2023; 41: 3116-3121
• 37 Schroth W, Hamann U, Fasching PA. et al. CYP2D6 polymorphisms as predictors of outcome in breast cancer patients treated with tamoxifen: expanded polymorphism coverage improves risk stratification. Clin Cancer Res 2010; 16: 4468-4477
• 38 Murdter TE, Schroth W, Bacchus-Gerybadze L. et al. Activity levels of tamoxifen metabolites at the estrogen receptor and the impact of genetic polymorphisms of phase I and II enzymes on their concentration levels in plasma. Clin Pharmacol Ther 2011; 89: 708-717
• 39 Province MA, Goetz MP, Brauch H. et al. CYP2D6 genotype and adjuvant tamoxifen: meta-analysis of heterogeneous study populations. Clin Pharmacol Ther 2014; 95: 216-227
• 40 Britt KL, Cuzick J, Phillips KA. Key steps for effective breast cancer prevention. Nat Rev Cancer 2020; 20: 417-436
• 41 Ditsch N, Wöcke A, Untch M. et al. AGO Recommendations for the Diagnosis and Treatment of Patients with Early Breast Cancer: Update 2022. Breast Care (Basel) 2022; 17: 403-420
• 42 Cuzick J, Chu K, Keevil B. et al. Effect of baseline oestradiol serum concentration on the efficacy of anastrozole for preventing breast cancer in postmenopausal women at high risk: a case-control study of the IBIS-II prevention trial. Lancet Oncol 2024; 25: 108-116
• 43 Pusztai L, Denkert C, OʼShaughnessy J. et al. Event-free survival by residual cancer burden with pembrolizumab in early-stage TNBC: exploratory analysis from KEYNOTE-522. Ann Oncol 2024; 35: 429-436
• 44 Dent R, Cortés J, Pusztai L. et al. Neoadjuvant pembrolizumab plus chemotherapy/adjuvant pembrolizumab for early-stage triple-negative breast cancer: quality-of-life results from the randomized KEYNOTE-522 study. J Natl Cancer Inst 2024; 116: 1654-1663
• 45 Schmid P, Cortes J, Dent R. et al. Event-free Survival with Pembrolizumab in Early Triple-Negative Breast Cancer. N Engl J Med 2022; 386: 556-567
• 46 Schmid P, Cortes J, Pusztai L. et al. Pembrolizumab for Early Triple-Negative Breast Cancer. N Engl J Med 2020; 382: 810-821
• 47 Schmid P, Cortes J, Dent R. et al. Overall Survival with Pembrolizumab in Early-Stage Triple-Negative Breast Cancer. N Engl J Med 2024; 391: 1981-1991
• 48 Loibl S, Schneeweiss A, Huober J. et al. Neoadjuvant durvalumab improves survival in early triple-negative breast cancer independent of pathological complete response. Ann Oncol 2022; 33: 1149-1158
• 49 Ignatiadis M, Bailey A, McArthur H. et al. Abstract GS01-03: Adding atezolizumab to adjuvant chemotherapy for stage II and III triple-negative breast cancer is unlikely to improve efficacy: interim analysis of the ALEXANDRA/IMpassion030 phase 3 trial. Cancer Res 2024; 84 (9_Supplement): GS01-3
• 50 Conte PF, Dieci MV, Bisagni G. et al. A-BRAVE trial: A phase III randomized trial with avelumab in early triple-negative breast cancer with residual disease after neoadjuvant chemotherapy or at high risk after primary surgery and adjuvant chemotherapy. J Clin Oncol 2024; 42 (17_suppl): LBA500
• 51 Kalinsky K, Barlow WE, Gralow JR. et al. 21-Gene Assay to Inform Chemotherapy Benefit in Node-Positive Breast Cancer. N Engl J Med 2021; 385: 2336-2347
• 52 Piccart M, van ʼt Veer LJ, Poncet C. et al. 70-gene signature as an aid for treatment decisions in early breast cancer: updated results of the phase 3 randomised MINDACT trial with an exploratory analysis by age. Lancet Oncol 2021; 22: 476-488
• 53 Sparano JA, Gray RJ, Makower DF. et al. Adjuvant Chemotherapy Guided by a 21-Gene Expression Assay in Breast Cancer. N Engl J Med 2018; 379: 111-121
• 54 Nitz UA, Gluz O, Kummel S. et al. Endocrine Therapy Response and 21-Gene Expression Assay for Therapy Guidance in HR+/HER2- Early Breast Cancer. J Clin Oncol 2022; 40: 2557-2567
• 55 Kalinsky KM, Barlow WE, Gralow JR. et al. Distant-disease free interval in participants (pts) with 1–3 positive lymph nodes (LN), hormone receptor-positive (HR+) and her2-negative (HER2-) breast cancer (BC) with recurrence score (RS) < or = 25 randomized to endocrine therapy (ET) ± chemotherapy (CT): SWOG s1007 (RxPONDER). San Antonio Breast Cancer Symposium 2021; 2021: GS2-07
• 56 Moolhuijsen LME, Visser JA. Anti-Mullerian Hormone and Ovarian Reserve: Update on Assessing Ovarian Function. J Clin Endocrinol Metab 2020; 105: 13
• 57 Anderson RA, Mansi J, Coleman RE. et al. The utility of anti-Mullerian hormone in the diagnosis and prediction of loss of ovarian function following chemotherapy for early breast cancer. Eur J Cancer 2017; 87: 58-64
• 58 Trapp E, Steidl J, Rack B. et al. Anti-Mullerian hormone (AMH) levels in premenopausal breast cancer patients treated with taxane-based adjuvant chemotherapy – A translational research project of the SUCCESS A study. Breast 2017; 35: 130-135
• 59 Ruddy KJ, Schaid DJ, Partridge AH. et al. Genetic predictors of chemotherapy-related amenorrhea in women with breast cancer. Fertil Steril 2019; 112: 731-739.e1
• 60 Kalinsky K, Barlow WE, Pathak HB. et al. Correlation of serum anti-Müllerian hormone (AMH) levels on identification of premenopausal patients (pts) with hormone receptor positive (HR+), HER2-negative, node-positive breast cancer most likely to benefit from adjuvant chemotherapy in SWOG S1007 (RxPONDER). J Clin Oncol 2024; 42 (16_suppl): 505
• 61 Johnston SRD, Toi M, OʼShaughnessy J. et al. Abemaciclib plus endocrine therapy for hormone receptor-positive, HER2-negative, node-positive, high-risk early breast cancer (monarchE): results from a preplanned interim analysis of a randomised, open-label, phase 3 trial. Lancet Oncol 2023; 24: 77-90
• 62 Harbeck N, Rastogi P, Martin M. et al. Adjuvant abemaciclib combined with endocrine therapy for high-risk early breast cancer: updated efficacy and Ki-67 analysis from the monarchE study. Ann Oncol 2021; 32: 1571-1581
• 63 Johnston SRD, Harbeck N, Hegg R. et al. Abemaciclib Combined With Endocrine Therapy for the Adjuvant Treatment of HR+, HER2-, Node-Positive, High-Risk, Early Breast Cancer (monarchE). J Clin Oncol 2020; 38: 3987-3998
• 64 Slamon D, Lipatov O, Nowecki Z. et al. Ribociclib plus Endocrine Therapy in Early Breast Cancer. N Engl J Med 2024; 390: 1080-1091
• 65 Fasching PA, Hack CC, Nabieva N. et al. Prognostic impact of selection criteria of current adjuvant endocrine therapy trials NATALEE and monarchE in postmenopausal HRpos/HER2neg breast cancer patients treated with upfront letrozole. Eur J Cancer 2024; 209: 114239
• 66 Schäffler H, Mergel F, Pfister K. et al. The Clinical Relevance of the NATALEE Study: Application of the NATALEE Criteria to a Real-World Cohort from Two Large German Breast Cancer Centers. Int J Mol Sci 2023; 24: 16366
• 67 Hack CC, Maass N, Aktas B. et al. Long-term Follow-up and Safety of Patients after an Upfront Therapy with Letrozole for Early Breast Cancer in Routine Clinical Care – The PreFace Study. Geburtshilfe Frauenheilkd 2024; 84: 185-195
• 68 Yardley DA, Untch M, Barrios sr. CH. et al. Baseline (BL) characteristics and efficacy endpoints for patients (pts) with node-negative (N0) HR+/HER2− early breast cancer (EBC): NATALEE trial. J Clin Oncol 2024; 42 (16_suppl): 512
• 69 Tolaney SM, Garrett-Mayer E, White J. et al. Updated Standardized Definitions for Efficacy End Points (STEEP) in Adjuvant Breast Cancer Clinical Trials: STEEP Version 2.0. J Clin Oncol 2021; 39: 2720-2731
• 70 Loi S, Johnston SRD, Arteaga CL. et al. Prognostic utility of ctDNA detection in the monarchE trial of adjuvant abemaciclib plus endocrine therapy (ET) in HR+, HER2-, node-positive, high-risk early breast cancer (EBC). J Clin Oncol 2024; 42 (17_suppl):: LBA507
• 71 clinicaltrials.gov. Standard Surveillance vs. Intensive Surveillance in Early Breast Cancer (SURVIVE). 2023. Accessed April 15, 2023 at: https://clinicaltrialsgov/ct2/show/NCT05658172
• 72 Hortobagyi GN, Stemmer SM, Burris HA. et al. Overall Survival with Ribociclib plus Letrozole in Advanced Breast Cancer. N Engl J Med 2022; 386: 942-950
• 73 Slamon DJ, Neven P, Chia S. et al. Overall Survival with Ribociclib plus Fulvestrant in Advanced Breast Cancer. N Engl J Med 2020; 382: 514-524
• 74 Im SA, Lu YS, Bardia A. et al. Overall Survival with Ribociclib plus Endocrine Therapy in Breast Cancer. N Engl J Med 2019; 381: 307-316
• 75 Sledge jr. GW, Toi M, Neven P. et al. The Effect of Abemaciclib Plus Fulvestrant on Overall Survival in Hormone Receptor-Positive, ERBB2-Negative Breast Cancer That Progressed on Endocrine Therapy-MONARCH 2: A Randomized Clinical Trial. JAMA Oncol 2020; 6: 116-124
• 76 Rugo HS, Bardia A, Marmé F. et al. Overall survival with sacituzumab govitecan in hormone receptor-positive and human epidermal growth factor receptor 2-negative metastatic breast cancer (TROPiCS-02): a randomised, open-label, multicentre, phase 3 trial. Lancet 2023; 402: 1423-1433
• 77 Modi S, Jacot W, Yamashita T. et al. Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer. N Engl J Med 2022; 387: 9-20
• 78 Turner NC, Oliveira M, Howell SJ. et al. Capivasertib in Hormone Receptor-Positive Advanced Breast Cancer. N Engl J Med 2023; 388: 2058-2070
• 79 Cortes J, Kim SB, Chung WP. et al. Trastuzumab Deruxtecan versus Trastuzumab Emtansine for Breast Cancer. N Engl J Med 2022; 386: 1143-1154
• 80 Murthy RK, Loi S, Okines A. et al. Tucatinib, Trastuzumab, and Capecitabine for HER2-Positive Metastatic Breast Cancer. N Engl J Med 2020; 382: 597-609
• 81 Cuzick J, Sestak I, Cawthorn S. et al. Tamoxifen for prevention of breast cancer: extended long-term follow-up of the IBIS-I breast cancer prevention trial. Lancet Oncol 2015; 16: 67-75
• 82 Goss PE, Ingle JN, Ales-Martinez JE. et al. Exemestane for breast-cancer prevention in postmenopausal women. N Engl J Med 2011; 364: 2381-2391
• 83 Fisher B, Costantino JP, Wickerham DL. et al. Tamoxifen for the prevention of breast cancer: current status of the National Surgical Adjuvant Breast and Bowel Project P-1 study. J Natl Cancer Inst 2005; 97: 1652-1662
• 84 Powles TJ, Ashley S, Tidy A. et al. Twenty-year follow-up of the Royal Marsden randomized, double-blinded tamoxifen breast cancer prevention trial. J Natl Cancer Inst 2007; 99: 283-290
• 85 Veronesi U, Maisonneuve P, Rotmensz N. et al. Tamoxifen for the prevention of breast cancer: late results of the Italian Randomized Tamoxifen Prevention Trial among women with hysterectomy. J Natl Cancer Inst 2007; 99: 727-737